Collins Helen Louise 4

What Happened
Helen Louise Collins, Chief Medical Officer of Enliven Therapeutics (ELVN), received two equity awards on February 12, 2026: 25,000 restricted stock units (RSUs) and 150,000 derivative awards (reported as a derivative grant). Both awards were issued at $0.00 per share (no cash paid).

Key Details

• Transaction date: 2026-02-12; Filing date: 2026-02-17 (filing appears late relative to the 2-business-day Form 4 deadline).
• Awards: 25,000 RSUs (acquired, $0) and 150,000 derivative shares (acquired, $0); total granted = 175,000 units.
• Reported value paid: $0.00 for both grants.
• Shares owned after the transaction: not stated in the information provided in this summary (not reported here).
• Footnotes:
  • F1 (applies to RSUs): Each RSU is a contingent right to one share. Vesting: 1/4 vests on March 1, 2027, then 1/16th vests each June 1, Sept 1, Dec 1, and March 1 thereafter, subject to continued service.
  • F2 (applies to derivative award/option): 1/4 of the option shares vest on February 12, 2027, then 1/48th vest each month thereafter, subject to continued service.

Context
These are awards (compensation grants), not open-market purchases or sales, so they reflect equity compensation rather than an immediate insider buy/sell signal. The RSUs convert to shares only as they vest; the derivative award appears to be an option-like grant with a separate monthly vesting schedule. The filing date (Feb 17) is later than the transaction date (Feb 12), indicating a late Form 4 filing, which investors should note for transparency/timeliness considerations.